Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,740
  • Shares Outstanding, K 146,130
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,050 K
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.63
Trade CTXR with:

Options Overview Details

View History
  • Implied Volatility 189.75% ( +6.60%)
  • Historical Volatility 39.65%
  • IV Percentile 64%
  • IV Rank 20.14%
  • IV High 664.39% on 05/16/22
  • IV Low 70.01% on 08/23/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 43
  • Volume Avg (30-Day) 225
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 46,613
  • Open Int (30-Day) 47,170

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +15.69%
on 11/09/22
1.2800 -7.81%
on 12/01/22
+0.1600 (+15.69%)
since 11/04/22
3-Month
1.0100 +16.83%
on 11/04/22
1.3800 -14.49%
on 09/09/22
-0.1200 (-9.23%)
since 09/02/22
52-Week
0.8306 +42.07%
on 06/21/22
2.0100 -41.29%
on 04/06/22
-0.3300 (-21.85%)
since 12/03/21

Most Recent Stories

More News
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that Citius will participate in the H.C. Wainwright...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Dawson James Thinks Citius Pharmaceuticals’ Stock is Going to Recover

Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) on July 12 and set a price target of $10.00. The company's shares closed last Friday at $0.91,...

CTXR : 1.1800 (-4.07%)
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...

CTXR : 1.1800 (-4.07%)
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.

NERV : 3.32 (-2.35%)
CRBP : 0.1290 (-1.60%)
CTXR : 1.1800 (-4.07%)
GMTX : 1.7000 (-1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 1.2752
2nd Resistance Point 1.2521
1st Resistance Point 1.2161
Last Price 1.1800
1st Support Level 1.1570
2nd Support Level 1.1339
3rd Support Level 1.0979

See More

52-Week High 2.0100
Fibonacci 61.8% 1.5595
Fibonacci 50% 1.4203
Fibonacci 38.2% 1.2811
Last Price 1.1800
52-Week Low 0.8306

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar